Indeed, targeting angiogenesis via disruption of vascular endothelial growth factor (VEGF) signaling is being considered for treating BC in combination with existing therapies (Petrylak et al., 2016; Sonpavde and Bellmunt, 2016). The gene discussed is VEGFA; the disease is breast cancer.